Umios (1333) · InitiativeRestated
New Entry into the Heparin Business
First written in FY2023-Q2. 1 of 3 entries say "Advanced", first in FY2023. Latest entry: FY2026-H1.
3entries
4years
0from disclosures
How it moved
Same theme, other companies
New Entry into the Heparin Business and Sales ExpansionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026-H1RestatedAnnual report
「Sales of heparin and materials for pharmaceutical products also remained firm, resulting in higher revenue.」
Sales of heparin and materials for pharmaceutical products remained firm, while the Company continued to develop new business in the fine chemicals field. - FY2023AdvancedAnnual report
「The Fine Chemicals Unit posted higher revenue and profit, as sales of heparin, which it entered this fiscal year, and existing sales to the health food market remained firm.」
Reported full-year results showing higher revenue and profit following entry into the heparin business, alongside existing sales to the health food market. - FY2023-Q2First statedAnnual report
「The Fine Chemicals Unit posted higher revenue and profit, supported by firm sales of heparin, which it entered this fiscal year, and sales to the health food market.」
Confirmed for the first time that the Fine Chemicals Unit entered the heparin sales business this fiscal year.